RP5063, a novel, multimodal, serotonin receptor modulator, prevents Sugen 5416-hypoxia–induced pulmonary arterial hypertension in rats

This publication has 37 references indexed in Scilit:

• Dopamine serotonin stabilizer RP5063: A randomized, double-blind, placebo-controlled multicenter trial of safety and efficacy in exacerbation of schizophrenia or schizoaffective disorder
  Schizophrenia Research, 2017
• Intratracheal Administration of Prostacyclin Analogue–incorporated Nanoparticles Ameliorates the Development of Monocrotaline and Sugen-Hypoxia-induced Pulmonary Arterial Hypertension
  Journal of Cardiovascular Pharmacology, 2016
• Riociguat for Patients With Pulmonary Hypertension Caused by Systolic Left Ventricular Dysfunction
  Circulation, 2013
• An Evaluation of Long-term Survival From Time of Diagnosis in Pulmonary Arterial Hypertension From the REVEAL Registry
  Chest, 2012
• New perspectives for the treatment of pulmonary hypertension
  British Journal of Pharmacology, 2011
• A noninvasive algorithm to exclude pre-capillary pulmonary hypertension
  European Respiratory Journal, 2010
• Formation of Plexiform Lesions in Experimental Severe Pulmonary Arterial Hypertension
  Circulation, 2010
• The Right Ventricle Under Pressure
  Chest, 2009
• Sildenafil in the treatment of pulmonary hypertension
  Vascular Health and Risk Management, 2006
• Long-Term Treatment With a Rho-Kinase Inhibitor Improves Monocrotaline-Induced Fatal Pulmonary Hypertension in Rats
  Circulation Research, 2004